Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients Apr 17, 2018 4:51pm EDT
Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy Apr 03, 2018 7:00am EDT
Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update Mar 06, 2018 4:01pm EST
Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America Mar 01, 2018 7:30am EST
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results Feb 27, 2018 7:30am EST
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Feb 16, 2018 5:15pm EST
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Jan 26, 2018 4:05pm EST
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Jan 05, 2018 4:05pm EST
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference Jan 04, 2018 7:30am EST
